|
KMID : 0370220100540020126
|
|
Yakhak Hoeji
2010 Volume.54 No. 2 p.126 ~ p.133
|
|
|
Cost-Utility Analysis of Bosentan Versus Iloprost in Korean Patients with Pulmonary Arterial Hypertension
|
|
Sohn Hyun-Soon
Lee Tae-Jin
|
|
|
Abstract
|
|
|
|
This study was conducted to analyze cost-utility of bosentan versus iloprost indicated for pulmonary arterial hypertension (PAH) in a Korean healthcare setting from a payer’s perspective. We constructed a Markov model to estimate total costs and outcomes for 1-year time horizon in a hypothetical cohort of 50-year-old patients with PAH. Base analysis showed that bosentan resulted in KW 5.5 billions saving and 18 quality-adjusted life year (QALY) gains per 100 patients compared to iloprost. Bosentan as a dominant strategy was found to be robust through various sensitivity analyses.
|
|
|
KEYWORD
|
|
|
cost-effectiveness, cost-utility, pulmonary arterial hypertension, bosentan, iloprost
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|